PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Thymosin Beta-4: Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for Thymosin Beta-4 across studied indications.

Back to Thymosin Beta-4 overview

Research Summary

Thymosin Beta-4 has been extensively studied in preclinical and clinical research for tissue repair, wound healing, and cardiac regeneration. Research demonstrates promising results in angiogenesis promotion, anti-fibrotic effects, and cardiovascular tissue repair. Note: TB-4 is on WADA's prohibited substances list for competitive sports.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Corneal healing Tier B 2 FDA-approved trials for neurotrophic keratitis show significant corneal repair
Wound healing Tier C 3 Accelerates dermal and corneal wound healing in multiple small trials
Cardiac repair Tier D 1 Preclinical data shows cardiomyocyte survival post-MI; human trials limited

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (6 sources)

  1. 1. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. Review

    Bock-Marquette I, Maar K, Maar S, Lippai B, Faskerti G, et al. (2023), International immunopharmacology

  2. 2. Thymosin β4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury. Review

    Bjørklund G, Dadar M, Aaseth J, Chirumbolo S (2020), Current medicinal chemistry

  3. 3. Thymosin β4 and Actin: Binding Modes, Biological Functions and Clinical Applications. Review

    Ying Y, Lin C, Tao N, Hoffman RD, Shi D, et al. (2023), Current protein & peptide science

  4. 4. Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease. Review

    Dubé KN, Smart N (2018), Expert opinion on biological therapy

  5. 5. Thymosin β4 and the anti-fibrotic switch. Study

    Kleinman HK, Kulik V, Goldstein AL (2023), International immunopharmacology

  6. 6. Thymosin β4 Deficiency Exacerbates Renal and Cardiac Injury in Angiotensin-II-Induced Hypertension. Clinical Trial

    Kumar N, Liao TD, Romero CA, Maheshwari M, Peterson EL, et al. (2018), Hypertension (Dallas, Tex. : 1979)